These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 20525274

  • 1. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.
    Fernández P, Trenholme A, Abarca K, Griffin MP, Hultquist M, Harris B, Losonsky GA, Motavizumab Study Group.
    BMC Pediatr; 2010 Jun 03; 10():38. PubMed ID: 20525274
    [Abstract] [Full Text] [Related]

  • 2. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.
    Feltes TF, Sondheimer HM, Tulloh RM, Harris BS, Jensen KM, Losonsky GA, Griffin MP, Motavizumab Cardiac Study Group.
    Pediatr Res; 2011 Aug 03; 70(2):186-91. PubMed ID: 21522037
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
    O'Brien KL, Chandran A, Weatherholtz R, Jafri HS, Griffin MP, Bellamy T, Millar EV, Jensen KM, Harris BS, Reid R, Moulton LH, Losonsky GA, Karron RA, Santosham M, Respiratory Syncytial Virus (RSV) Prevention study group.
    Lancet Infect Dis; 2015 Dec 03; 15(12):1398-408. PubMed ID: 26511956
    [Abstract] [Full Text] [Related]

  • 4. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children.
    Abarca K, Jung E, Fernández P, Zhao L, Harris B, Connor EM, Losonsky GA, Motavizumab Study Group.
    Pediatr Infect Dis J; 2009 Apr 03; 28(4):267-72. PubMed ID: 19258920
    [Abstract] [Full Text] [Related]

  • 5. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
    Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA.
    J Mol Biol; 2007 May 04; 368(3):652-65. PubMed ID: 17362988
    [Abstract] [Full Text] [Related]

  • 6. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B.
    Cochrane Database Syst Rev; 2013 Apr 30; (4):CD006602. PubMed ID: 23633336
    [Abstract] [Full Text] [Related]

  • 7. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group.
    Sáez-Llorens X, Castaño E, Null D, Steichen J, Sánchez PJ, Ramilo O, Top FH, Connor E.
    Pediatr Infect Dis J; 1998 Sep 30; 17(9):787-91. PubMed ID: 9779762
    [Abstract] [Full Text] [Related]

  • 8. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep 30; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [Abstract] [Full Text] [Related]

  • 9. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
    Man WH, Scheltema NM, Clerc M, van Houten MA, Nibbelke EE, Achten NB, Arp K, Sanders EAM, Bont LJ, Bogaert D.
    Lancet Respir Med; 2020 Oct 30; 8(10):1022-1031. PubMed ID: 32203712
    [Abstract] [Full Text] [Related]

  • 10. Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations.
    Weisman LE.
    Curr Opin Mol Ther; 2009 Apr 30; 11(2):208-18. PubMed ID: 19330726
    [Abstract] [Full Text] [Related]

  • 11. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
    Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ.
    J Manag Care Pharm; 2010 Apr 30; 16(1):46-58. PubMed ID: 20131495
    [Abstract] [Full Text] [Related]

  • 12. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
    Resch B.
    Hum Vaccin Immunother; 2017 Sep 02; 13(9):2138-2149. PubMed ID: 28605249
    [Abstract] [Full Text] [Related]

  • 13. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.
    Fenton C, Scott LJ, Plosker GL.
    Paediatr Drugs; 2004 Sep 02; 6(3):177-97. PubMed ID: 15170364
    [Abstract] [Full Text] [Related]

  • 14. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
    Pediatrics; 1998 Nov 02; 102(5):1211-6. PubMed ID: 9794957
    [Abstract] [Full Text] [Related]

  • 15. A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation.
    Turti TV, Baibarina EN, Degtiareva EA, Keshishyan ES, Lobzin YV, Namazova-Вaranova LS, Prodeus AP, Gudkov KM, Kruglova AI, Schulz GA, Notario GF.
    BMC Res Notes; 2012 Sep 04; 5():484. PubMed ID: 22943074
    [Abstract] [Full Text] [Related]

  • 16. Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis.
    La Via WV, Notario GF, Yu XQ, Sharma S, Noertersheuser PA, Robbie GJ.
    Pulm Pharmacol Ther; 2013 Dec 04; 26(6):666-71. PubMed ID: 23523663
    [Abstract] [Full Text] [Related]

  • 17. Safety and immunogenicity of palivizumab (Synagis) administered for two seasons.
    Null D, Pollara B, Dennehy PH, Steichen J, Sánchez PJ, Givner LB, Carlin D, Landry B, Top FH, Connor E.
    Pediatr Infect Dis J; 2005 Nov 04; 24(11):1021-3. PubMed ID: 16282947
    [Abstract] [Full Text] [Related]

  • 18. Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY).
    Tuffy KM, Ahani B, Domachowske JB, Furuno K, Ji H, Madhi SA, Mankad VS, Hamrén UW, Villafana T, Wang Y, Kelly EJ, Wilkins D.
    Vaccine; 2024 Oct 24; 42(24):126276. PubMed ID: 39241352
    [Abstract] [Full Text] [Related]

  • 19. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children.
    Lagos R, DeVincenzo JP, Muñoz A, Hultquist M, Suzich J, Connor EM, Losonsky GA.
    Pediatr Infect Dis J; 2009 Sep 24; 28(9):835-7. PubMed ID: 19636278
    [Abstract] [Full Text] [Related]

  • 20. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
    Cutrera R, Wolfler A, Picone S, Rossi GA, Gualberti G, Merolla R, Del Vecchio A, Villani A, Midulla F, Dotta A.
    Ital J Pediatr; 2019 Nov 09; 45(1):139. PubMed ID: 31706338
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.